Tuesday, 6 November 2018

Mundipharma signs licensing agreement with Moberg Pharma to bring leading fungal nail treatment to MEA region





Emtrix®, the leading treatment for patients suffering from nail fungus and nail psoriasis, will be licensed by Mundipharma from the Swedish pharmaceutical company and to be marketed as part of the popular BETADINE® Infectious Disease portfolio


5 November, Dubai: Mundipharma has signed a new agreement with Moberg Pharma, a specialist in topical treatments for nail and skin diseases, to commercialize its consumer healthcare product for the treatment of nail diseases in the Middle East and Africa (MEA).


An innovative and rapidly growing company, Moberg Pharma is one of the leading players in the treatment of nail diseases. Moberg Pharma is promoting its brands in the US and UK as well through distributors across more than 30 countries.

Under the agreement Mundipharma will license and introduce Emtrix® as part of Mundipharma’s Betadine®range of infectious disease therapies. Used to treat discolored and deformed nails resulting from fungal infection or psoriasis, Emtrix® improves the appearance of damaged nails by reducing discoloration, normalizing thickness, and hydrating brittle nails. 1-4

Onychomycosis is fungal infection of the nail, characterized by thickening, splitting, roughening and discoloration of the nail. This condition may affect toenails or fingernails, but toenail infections are particularly more common. It is estimated that about 2% to 13.8% of adults are affected by onychomycosis,5–7 and the prevalence increases with age reaching 25–30% in the elderly.6


Infections can be painful, have a negative impact on a patient’s self-image and are associated with increased risk of secondary infection. If left untreated, onychomycosis can cause serious limitations to a sufferer’s mobility.1

Ashraf Allam, Mundipharma’s Vice President for Middle, Turkey and Africa region, said: “The agreement with Moberg Pharma is a major boost to Mundipharma’s plans to expand its operations in to new markets and to bring an even greater choice of healthcare products to our customers in MEA.

This newly signed partnership means patients will be able to access one of the leading treatments for this common and uncomfortable condition.

Mundipharma is committed to offering the latest in market-leading healthcare products to patients across MEA bringing about effective and sustained improvement in people with onychomycosis infections in the Middle East and Africa Region.”

“We look forward to developing our relationship with Mundipharma and making Emtrix® available in new regions as we expand our footprint in growing markets”, says Peter Wolpert, Moberg Pharma’s CEO.
=